Commentary
thumbnail
Global Markets
Planning, patient, and payer problems hurting gene therapy rolloutsPlanning, patient, and payer problems hurting gene therapies
“Horrible” gene therapy launches, epitomized by BioMarin’s lackluster and limited rollout of Roctavian, are jeopardizing the sector, according to Dark Horse consultant Anthony Davies.
Subscribe to receive our monthly print or digital publication
Join our 70,000+ readers. And yes, it's completely free.